IHP Special Report

Hurdles To Patient Engagement: The New Frontier In Drug Development (Part 2)

August 27, 2015 at 1:01 PM
This is part two of an FDA Week Special Report on patient engagement in the drug development process. Part one focused on the methods FDA and other stakeholders are taking to better engage patients. Part two looks at the regulatory and technological hurdles involved in bringing real-world patient data into the drug development process. The influence of patient-generated data in the drug development process is becoming more apparent as health care stakeholders and even FDA begin to embrace...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.